Patient‐reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial

Abstract Background We evaluated patient‐reported outcomes (PRO) during neoadjuvant androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) followed by either adjuvant continuous ADT (CADT) or intermittent ADT (IADT) for patients with locally advanced prostate cancer (Pca). Me...

Full description

Bibliographic Details
Main Authors: Akira Yokomizo, Hirofumi Koga, Kazuto Ito, Yutaka Takezawa, Motokiyo Komiyama, Kazuo Nishimura, Junji Yonese, Katsuyoshi Hashine, Naoya Masumori, Gaku Arai, Shiro Saito, Mitsuru Shinohara, Nobuaki Shimizu, Atsushi Yamauchi, Takefumi Satoh, Tatsuo Tochigi, Mikio Kobayashi, Hiroyuki Fujimoto, Ken‐ichi Kakimoto, Iwao Fukui, Taiji Tsukamoto, Miwako Nozaki, Katsuyuki Karasawa, Masaru Hasumi, Mikinobu Ohtani, Hiromichi Ishiyama, Masaaki Kuwahara, Masaoki Harada, Yasuo Ohashi, Toshihiko Kotake, Tadao Kakizoe, Kazuhiro Suzuki, Seiji Naito, Hidetoshi Yamanaka, National Research Project on Endocrine‐Radiation Combination Therapy for Locally Advanced Prostate Cancer investigators
Format: Article
Language:English
Published: Wiley 2021-05-01
Series:Cancer Medicine
Subjects:
QOL
Online Access:https://doi.org/10.1002/cam4.3895
id doaj-4fc6d5a819fc4ff3b13b667c17fde309
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Akira Yokomizo
Hirofumi Koga
Kazuto Ito
Yutaka Takezawa
Motokiyo Komiyama
Kazuo Nishimura
Junji Yonese
Katsuyoshi Hashine
Naoya Masumori
Gaku Arai
Shiro Saito
Mitsuru Shinohara
Nobuaki Shimizu
Atsushi Yamauchi
Takefumi Satoh
Tatsuo Tochigi
Mikio Kobayashi
Hiroyuki Fujimoto
Ken‐ichi Kakimoto
Iwao Fukui
Taiji Tsukamoto
Miwako Nozaki
Katsuyuki Karasawa
Masaru Hasumi
Mikinobu Ohtani
Hiromichi Ishiyama
Masaaki Kuwahara
Masaoki Harada
Yasuo Ohashi
Toshihiko Kotake
Tadao Kakizoe
Kazuhiro Suzuki
Seiji Naito
Hidetoshi Yamanaka
National Research Project on Endocrine‐Radiation Combination Therapy for Locally Advanced Prostate Cancer investigators
spellingShingle Akira Yokomizo
Hirofumi Koga
Kazuto Ito
Yutaka Takezawa
Motokiyo Komiyama
Kazuo Nishimura
Junji Yonese
Katsuyoshi Hashine
Naoya Masumori
Gaku Arai
Shiro Saito
Mitsuru Shinohara
Nobuaki Shimizu
Atsushi Yamauchi
Takefumi Satoh
Tatsuo Tochigi
Mikio Kobayashi
Hiroyuki Fujimoto
Ken‐ichi Kakimoto
Iwao Fukui
Taiji Tsukamoto
Miwako Nozaki
Katsuyuki Karasawa
Masaru Hasumi
Mikinobu Ohtani
Hiromichi Ishiyama
Masaaki Kuwahara
Masaoki Harada
Yasuo Ohashi
Toshihiko Kotake
Tadao Kakizoe
Kazuhiro Suzuki
Seiji Naito
Hidetoshi Yamanaka
National Research Project on Endocrine‐Radiation Combination Therapy for Locally Advanced Prostate Cancer investigators
Patient‐reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial
Cancer Medicine
external beam radiation therapy
intermittent androgen deprivation therapy
prostate cancer
QOL
neoadjuvant
author_facet Akira Yokomizo
Hirofumi Koga
Kazuto Ito
Yutaka Takezawa
Motokiyo Komiyama
Kazuo Nishimura
Junji Yonese
Katsuyoshi Hashine
Naoya Masumori
Gaku Arai
Shiro Saito
Mitsuru Shinohara
Nobuaki Shimizu
Atsushi Yamauchi
Takefumi Satoh
Tatsuo Tochigi
Mikio Kobayashi
Hiroyuki Fujimoto
Ken‐ichi Kakimoto
Iwao Fukui
Taiji Tsukamoto
Miwako Nozaki
Katsuyuki Karasawa
Masaru Hasumi
Mikinobu Ohtani
Hiromichi Ishiyama
Masaaki Kuwahara
Masaoki Harada
Yasuo Ohashi
Toshihiko Kotake
Tadao Kakizoe
Kazuhiro Suzuki
Seiji Naito
Hidetoshi Yamanaka
National Research Project on Endocrine‐Radiation Combination Therapy for Locally Advanced Prostate Cancer investigators
author_sort Akira Yokomizo
title Patient‐reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial
title_short Patient‐reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial
title_full Patient‐reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial
title_fullStr Patient‐reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial
title_full_unstemmed Patient‐reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trial
title_sort patient‐reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: a randomized phase iii trial
publisher Wiley
series Cancer Medicine
issn 2045-7634
publishDate 2021-05-01
description Abstract Background We evaluated patient‐reported outcomes (PRO) during neoadjuvant androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) followed by either adjuvant continuous ADT (CADT) or intermittent ADT (IADT) for patients with locally advanced prostate cancer (Pca). Methods A multicenter, randomized phase III trial enrolled 303 patients with locally advanced Pca. The patients were treated with 6 months (M) of ADT followed by 72 Gy of EBRT, and were randomly assigned to CADT or IADT after 14 M. The PROs were evaluated at sic points: baseline, 6 M, 8 M, 14 M, 20 M, and 38 M using FACT‐P questionnaires and EPIC urinary, bowel, and sexual bother subscales. Results The FACT‐P total scores were significantly better (p < 0.05) in IADT versus CADT at 20 M (121.6 vs.115.4) and at 38 M (119.9 vs. 115.2). The physical well‐being scores (PWB) were significantly better (p < 0.05) in IADT versus CADT at 38 M (25.4 vs. 24.0). The functional scores were significantly better in IADT than those in CADT at 14 M (20.2 vs18.7, p < 0.05) and at 20 M (21.0 vs.18.9, p < 0.05). Conclusion The PRO was significantly favorable in IADT on FACT‐P total score at 20 M and 38 M, PWB and functional scores at 38 M.
topic external beam radiation therapy
intermittent androgen deprivation therapy
prostate cancer
QOL
neoadjuvant
url https://doi.org/10.1002/cam4.3895
work_keys_str_mv AT akirayokomizo patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT hirofumikoga patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT kazutoito patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT yutakatakezawa patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT motokiyokomiyama patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT kazuonishimura patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT junjiyonese patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT katsuyoshihashine patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT naoyamasumori patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT gakuarai patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT shirosaito patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT mitsurushinohara patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT nobuakishimizu patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT atsushiyamauchi patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT takefumisatoh patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT tatsuotochigi patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT mikiokobayashi patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT hiroyukifujimoto patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT kenichikakimoto patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT iwaofukui patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT taijitsukamoto patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT miwakonozaki patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT katsuyukikarasawa patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT masaruhasumi patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT mikinobuohtani patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT hiromichiishiyama patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT masaakikuwahara patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT masaokiharada patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT yasuoohashi patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT toshihikokotake patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT tadaokakizoe patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT kazuhirosuzuki patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT seijinaito patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT hidetoshiyamanaka patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
AT nationalresearchprojectonendocrineradiationcombinationtherapyforlocallyadvancedprostatecancerinvestigators patientreportedoutcomesfollowingneoadjuvantendocrinetherapyexternalbeamradiationandadjuvantcontinuousintermittentendocrinetherapyforlocallyadvancedprostatecancerarandomizedphaseiiitrial
_version_ 1721439910169149440
spelling doaj-4fc6d5a819fc4ff3b13b667c17fde3092021-05-16T07:45:27ZengWileyCancer Medicine2045-76342021-05-0110103240324810.1002/cam4.3895Patient‐reported outcomes following neoadjuvant endocrine therapy, external beam radiation, and adjuvant continuous/intermittent endocrine therapy for locally advanced prostate cancer: A randomized phase III trialAkira Yokomizo0Hirofumi Koga1Kazuto Ito2Yutaka Takezawa3Motokiyo Komiyama4Kazuo Nishimura5Junji Yonese6Katsuyoshi Hashine7Naoya Masumori8Gaku Arai9Shiro Saito10Mitsuru Shinohara11Nobuaki Shimizu12Atsushi Yamauchi13Takefumi Satoh14Tatsuo Tochigi15Mikio Kobayashi16Hiroyuki Fujimoto17Ken‐ichi Kakimoto18Iwao Fukui19Taiji Tsukamoto20Miwako Nozaki21Katsuyuki Karasawa22Masaru Hasumi23Mikinobu Ohtani24Hiromichi Ishiyama25Masaaki Kuwahara26Masaoki Harada27Yasuo Ohashi28Toshihiko Kotake29Tadao Kakizoe30Kazuhiro Suzuki31Seiji Naito32Hidetoshi Yamanaka33National Research Project on Endocrine‐Radiation Combination Therapy for Locally Advanced Prostate Cancer investigatorsDepartment of Urology Graduate School of Medicine Kyusyu University Fukuoka JapanDepartment of Urology Graduate School of Medicine Kyusyu University Fukuoka JapanDepartment of Urology Gunma University Graduate School of Medicine Maebashi JapanDepartment of Urology Isesaki Municipal Hospital Isesaki JapanDepartment of Urology National Cancer Center Hospital Tokyo JapanDepartment of Urology Osaka International Cancer Institute Osaka JapanDepartment of Urology Cancer Institute Hospital Tokyo JapanDepartment of Urology Shikoku Cancer Center Matsuyama JapanDepartment of Urology Sapporo Medical University School of Medicine Sapporo JapanDepartment of Urology Dokkyo University Koshigaya Hospital Koshigaya JapanDepartment of Urology Tokyo Medical Center Tokyo JapanDepartment of Urology Tokyo Metropolitan Komagome Hospital Tokyo JapanDepartment of Urology Gunma Cancer Center Hospital Ohta JapanDepartment of Urology Ibaraki Prefectural Central Hospital Kasama JapanDepartment of Urology Kitasato University School of Medicine Sagamihara JapanDepartment of Urology Miyagi Cancer Center Natori JapanDepartment of Urology Isesaki Municipal Hospital Isesaki JapanDepartment of Urology National Cancer Center Hospital Tokyo JapanDepartment of Urology Osaka International Cancer Institute Osaka JapanDepartment of Urology Cancer Institute Hospital Tokyo JapanSapporo Medical University School of Medicine Sapporo JapanDepartment of Radiation Oncology Dokkyo University Koshigaya Hospital Koshigaya JapanDepartment of Radiation Oncology Tokyo Metropolitan Komagome Hospital Tokyo JapanDepartment of Urology Gunma Cancer Center Hospital Ohta JapanDepartment of Urology Ibaraki Prefectural Central Hospital Kasama JapanDepartment of Radiation and Radiation Oncology Kitasato University Sagamihara JapanSendai Jin‐hinyokika Sendai JapanKanagawa Cancer Center Yokohama JapanUniversity of Tokyo Tokyo JapanKotake Clinic Osaka JapanPresident, Japan Cancer Society Tokyo JapanDepartment of Urology Gunma University Graduate School of Medicine Maebashi JapanDepartment of Urology Graduate School of Medicine Kyusyu University Fukuoka JapanInstitute for Preventive Medicine Kurosawa Hospital Takasaki JapanAbstract Background We evaluated patient‐reported outcomes (PRO) during neoadjuvant androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) followed by either adjuvant continuous ADT (CADT) or intermittent ADT (IADT) for patients with locally advanced prostate cancer (Pca). Methods A multicenter, randomized phase III trial enrolled 303 patients with locally advanced Pca. The patients were treated with 6 months (M) of ADT followed by 72 Gy of EBRT, and were randomly assigned to CADT or IADT after 14 M. The PROs were evaluated at sic points: baseline, 6 M, 8 M, 14 M, 20 M, and 38 M using FACT‐P questionnaires and EPIC urinary, bowel, and sexual bother subscales. Results The FACT‐P total scores were significantly better (p < 0.05) in IADT versus CADT at 20 M (121.6 vs.115.4) and at 38 M (119.9 vs. 115.2). The physical well‐being scores (PWB) were significantly better (p < 0.05) in IADT versus CADT at 38 M (25.4 vs. 24.0). The functional scores were significantly better in IADT than those in CADT at 14 M (20.2 vs18.7, p < 0.05) and at 20 M (21.0 vs.18.9, p < 0.05). Conclusion The PRO was significantly favorable in IADT on FACT‐P total score at 20 M and 38 M, PWB and functional scores at 38 M.https://doi.org/10.1002/cam4.3895external beam radiation therapyintermittent androgen deprivation therapyprostate cancerQOLneoadjuvant